Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

1.020 -0.050 (-4.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 174,506
Open 1.090
Bid (Size) 1.000 (5)
Ask (Size) 1.030 (97)
Prev. Close 1.070
Today's Range 1.020 - 1.098
52wk Range 0.7300 - 11.18
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Via TheNewswire.com
Exposures Product Safety

Performance

YTD
-58.9%
-58.9%
1 Month
N/A
N/A
3 Month
-33.3%
-33.3%
6 Month
-66.1%
-66.1%
1 Year
-37.4%
-37.4%

More News

Read More
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance
Via NewMediaWire
Exposures COVID-19 Product Safety
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance
Via TheNewswire.com
Exposures COVID-19 Product Safety
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
Via NewMediaWire
Topics Artificial Intelligence Economy Supply Chain
Exposures Artificial Intelligence Supply Chain
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
Via TheNewswire.com
Topics Artificial Intelligence Economy Supply Chain
Exposures Artificial Intelligence Supply Chain
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
Via TheNewswire.com
Exposures COVID-19
GeoVax Expands Gedeptin(R) Patent Portfolio
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Via TheNewswire.com
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
Via NewMediaWire
Exposures COVID-19
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
Via NewMediaWire
Exposures COVID-19
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
Via TheNewswire.com
Exposures COVID-19
GeoVax Expands Gedeptin(R) Patent Portfolio
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Via NewMediaWire
Topics Economy Government
Exposures COVID-19 Political Supply Chain
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Via TheNewswire.com
Topics Economy Government
Exposures COVID-19 Political Supply Chain
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
Via NewMediaWire
Exposures COVID-19
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
Via TheNewswire.com
Exposures COVID-19
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Via NewMediaWire
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
Via TheNewswire.com
Topics Supply Chain
Exposures Supply Chain
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
Via NewMediaWire
Topics Supply Chain
Exposures Supply Chain
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
Via NewMediaWire
Exposures COVID-19
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
Via TheNewswire.com
Exposures COVID-19
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
Via NewMediaWire
Exposures COVID-19
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
Via TheNewswire.com
Exposures COVID-19

Frequently Asked Questions

Is GeoVax Labs, Inc. - Common Stock publicly traded?
Yes, GeoVax Labs, Inc. - Common Stock is publicly traded.
What exchange does GeoVax Labs, Inc. - Common Stock trade on?
GeoVax Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeoVax Labs, Inc. - Common Stock?
The ticker symbol for GeoVax Labs, Inc. - Common Stock is GOVX on the Nasdaq Stock Market
What is the current price of GeoVax Labs, Inc. - Common Stock?
The current price of GeoVax Labs, Inc. - Common Stock is 1.020
When was GeoVax Labs, Inc. - Common Stock last traded?
The last trade of GeoVax Labs, Inc. - Common Stock was at 05/30/25 04:00 PM ET
What is the market capitalization of GeoVax Labs, Inc. - Common Stock?
The market capitalization of GeoVax Labs, Inc. - Common Stock is 2.22M
How many shares of GeoVax Labs, Inc. - Common Stock are outstanding?
GeoVax Labs, Inc. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.